Trial Profile
A Randomized, Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 15 Jun 2018 Results of pooled data from 14 trials, were published in the Journal of Clinical Pharmacology.
- 10 Nov 2013 New trial record